Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years of age with any of the following: Histopathologically confirmed DLBCL or HGBL (i.e., HGBL with MYC, BCL2, and/or BCL6 rearrangements, HGBL, not otherwise specified \[NOS\], or DLBCL, NOS) that is refractory to, or has relapsed after, treatment with at least 1 prior regimen. Eligible sub-types include DHL, THL, or DEL, as well as DLBCL or HGBL without MYC and/or BCL2 alterations. Criteria for DHL are concurrent MYC translocation+ and BCL2 translocation+ by fluorescence in situ hybridization (FISH) (same criteria for THL, which also includes BCL6 translocation+ by FISH); criteria for DEL are concurrent overexpression of MYC (≥ 40%) and BCL2 (\> 50%) by immunohistochemistry (IHC).~* Measurable disease by CT or PET/CT. MRI acceptable as per protocol.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.~* Recovery to Grade 1 or baseline of any toxicity due to prior systemic treatments (excluding alopecia).~* Absolute neutrophil count ≥ 1,000/µL; platelets ≥ 75,000/µL for patients with no bone marrow involvement by malignancy; platelets ≥ 50,000/µL for patients with bone marrow involvement by malignancy.~* Creatinine ≤ 1.5x upper limit of normal (ULN); total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN.~* Life expectancy of at least 3 months.~Exclusion Criteria:~* Intention to undergo stem cell transplant (SCT) or treatment with chimeric antigen receptor (CAR) T-cell therapy.~* SCT therapy within 100 days prior to starting study treatment.~* Systemic anti-cancer therapy or investigational agent within 3 weeks of study entry, except for nitrosoureas or mitomycin C (6 weeks).~* Other non-cytotoxic anti-cancer therapy or investigational agent within 5 half-lives or 21 days prior to study treatment, whichever is shorter, as long as any drug related toxicities have resolved to Grade 1 or less. Dexamethasone up to 12 mg/d is allowed as supportive therapy and does not exclude participation.~* Contraindication to venetoclax or rituximab.~* Progressive disease during treatment or within 3 months of stopping prior treatment with a BCL2 inhibitor, histone deacetylase (HDAC) inhibitor, or phosphoinositide-3 kinase (PI3k) inhibitor, or prior discontinuation of any of these therapies due to clinically significant toxicity.~* Graft vs. host disease following prior allogeneic transplant within 3 months prior to study treatment.~* Ongoing treatment with chronic immunosuppressants.~* Active CNS lymphoma.~* Known gastrointestinal condition that would interfere with swallowing or the oral absorption or tolerance of fimepinostat.~* Serious infection requiring systemic antibiotic therapy within 14 days prior to study treatment.~* Uncontrolled or severe cardiovascular disease~* Unstable or clinically significant concurrent medical condition.~* Second primary malignancy within 2 years of study entry other than what is specified in the protocol.~* Known HIV positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.~* Active CMV infection, presence of CMV antigenemia, or evidence of any invasive CMV end organ disease (e.g., CMV colitis).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fimepinostat - Continuous Once Daily (Type: EXPERIMENTAL): Fimepinostat 30-60 mg/day
- Fimepinostat - 2x/week (Type: EXPERIMENTAL): Fimepinostat 60-240 mg/day
- Fimepinostat - 3x/week (Type: EXPERIMENTAL): Fimepinostat 60-180 mg/day
- Fimepinostat - 4x/week (Type: EXPERIMENTAL): Fimepinosta 60-180 mg/day
- Fimepinostat - 5x/week (Type: EXPERIMENTAL): Fimepinostat 60-180 mg/day
- Fimepinostat - Expansion 5x/week (Type: EXPERIMENTAL): Fimepinostat 60 mg on the 5 days on/2 days off
- Fimepinostat - Expansion 3x/week (Type: EXPERIMENTAL): Fimepinostat 120 mg 3 days on/4 days off
- Fimepinostat 60 mg - Combination w/ rituximab (Type: EXPERIMENTAL): Fimepinostat 60 mg 5 days on.2 days off plus rituximab
- Fimepinostat 120 mg - Combination w/ rituximab (Type: EXPERIMENTAL): Fimepinostat 120 mg 3x/week plus rituximab
- Fimepinostat - Biocomparability Arm (Type: EXPERIMENTAL): Biocomparability Arm
- Fimepinostat 30 mg - Combination w/ venetoclax (Type: EXPERIMENTAL): Fimepinostat 30 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
- Fimepinostat 60 mg - Combination w/ venetoclax (Type: EXPERIMENTAL): Fimepinostat 60 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
- Fimepinostat - Combination w/ venetoclax and rituximab (Type: EXPERIMENTAL): Fimepinostat and venetoclax dosed at dose levels determined for that combination. Rituximab dosed at 375 mg/m2 IV on Day 1 of each 21 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete